NCT02980315Unknown1 期
A New Efficient EBV AssociatedTechnologies of T Cells in Treating Malignant Tumors and Clinical Application
The Second Hospital of Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2016年11月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- all cause mortality
研究概览
简要总结
The purpose of this study is to evaluate the safety of the designed LMP1-CAR -T cells and determine whether the CAR-T cells are effective in the treatment of EBV associated malignant tumors.
详细描述
Half of the patients will treat with LMP1-CAR-T cells,while the other half will receive a placebo.During the time of the treatment ,we will supervise the side effect of treated group.At last we compare the survival rate and health condition of the two groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of nasopharyngeal carcinoma
排除标准
- ••pregnant woman
- •severe autoimmune diseases
- •serious infection
结局指标
主要结局
all cause mortality
时间窗: one year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
早期 1 期
EBV CAR-T Cells for Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT05654077The Affiliated Hospital of Xuzhou Medical University24
进行中（未招募）
1 期
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Lymphoplasmacytic LymphomaRefractory Mantle Cell LymphomaRefractory Transformed Non-Hodgkin LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Marginal Zone LymphomaRefractory Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic LymphomaRecurrent Central Nervous System LymphomaRefractory Central Nervous System LymphomaNCT03277729Fred Hutchinson Cancer Center53
已完成
1 期
A Study of the Safety and Efficacy of EBV Specific T-cell LinesEpstein-Barr Virus InfectionsLymphomaPost-Transplant Lymphoproliferative DisorderNCT02580539Dr. Jean-Sebastien Delisle, MD, PhD12
Unknown
1 期
Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaLeukemia, Myeloid, AcuteNCT05008575Xinqiao Hospital of Chongqing27
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionSolid Tumor, AdultSolid TumorPancreatic NeoplasmsPancreas CancerNon Small Cell Lung CancerNon Small Cell Lung Cancer RecurrentNon-Small Cell Squamous Lung CancerNSCLC, RecurrentColorectal AdenocarcinomaColorectal Cancer MetastaticColorectal CancerPancreatic CancerNSCLCColorectal NeoplasmsCancerCRCNCT05736731A2 Biotherapeutics Inc.160